Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review
February 11, 2020 01:15 ET
|
Novartis International AG
FDA Priority Review for capmatinib based on Phase II data in first-line and previously treated patients with MET exon 14 skipping (METex14) mutated advanced non-small cell lung cancer...
Sandoz completes acquisition of Aspen’s Japanese operations, strengthening its position in world’s third largest market for generics and off-patent medicines
January 31, 2020 01:30 ET
|
Novartis International AG
Successful acquisition of Aspen’s Japanese operations and assets reinforces strategic focus on Japan, world’s third largest market for generics and off-patent medicinesAcquired portfolio complements...
Novartis a réalisé en 2019 une forte croissance de son chiffre d’affaires, une augmentation de sa marge et une percée dans l’innovation en lançant cinq nouvelles entités moléculaires
January 29, 2020 01:00 ET
|
Novartis International AG
Hausse du chiffre d’affaires net des activités poursuivies1 de 9% sur l’exercice entier (tcc2, +6% USD): Pharmaceuticals: cette unité opérationnelle progresse de 12% (tcc), sous l’impulsion de...
Novartis erzielt 2019 ein starkes Umsatzwachstum, Margen-steigerungen und bahnbrechende Innovationen mit der Markt¬einführung fünf neuer Wirkstoffe
January 29, 2020 01:00 ET
|
Novartis International AG
Der Nettoumsatz der fortzuführenden Geschäftsbereiche1 steigt 2019 um 9% (kWk2, +6% USD): Die Geschäftseinheit Pharmaceuticals wächst um 12% (kWk), getragen von Cosentyx (USD 3,6 Milliarden,...
Novartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019
January 29, 2020 01:00 ET
|
Novartis International AG
Full year net sales for continuing operations1 up 9% (cc2, +6% USD): Pharmaceuticals BU growing 12% (cc) driven by Cosentyx USD 3.6 billion (+28% cc), Entresto USD 1.7 billion (+71% cc) and...
Novartis announces EU approval of Mayzent® (siponimod) for adult patients with secondary progressive multiple sclerosis (SPMS) with active disease
January 20, 2020 09:32 ET
|
Novartis International AG
Mayzent® (siponimod) is the first and only oral treatment specifically indicated for patients with secondary progressive multiple sclerosis (SPMS) with active disease in Europe1 Mayzent addresses an...
Novartis successfully completes acquisition of The Medicines Company, adding a potentially first-in-class, investigational cholesterol-lowering therapy inclisiran
January 06, 2020 12:05 ET
|
Novartis International AG
Over 50 million secondary prevention patients worldwide with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) on current standard of care do not achieve LDL...
Novartis completes tender offer for all outstanding shares of The Medicines Company
January 06, 2020 01:00 ET
|
Novartis International AG
Basel, January 6, 2020 — Novartis AG (NYSE: NVS) (“Novartis”) today announced the successful completion of the previously announced tender offer by its indirect wholly-owned subsidiary, Medusa Merger...
Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma
December 16, 2019 01:15 ET
|
Novartis International AG
Pooled analyses of LUSTER 1 and 2 did not support further development of Fevipiprant in asthma as a primary indication Fevipiprant was well tolerated with adverse events balanced across treatment...
Novartis receives positive CHMP opinion for Beovu® (brolucizumab) for the treatment of wet AMD
December 13, 2019 07:03 ET
|
Novartis International AG
In two head-to-head clinical trials, patients on Beovu achieved vision gains that were non-inferior to aflibercept at year one1 In a pre-specified secondary endpoint, fewer patients had intra-retinal...